دورية أكاديمية
أعرض في EDS

Neuroendocrine breast carcinoma: a rare but challenging entity.

التفاصيل البيبلوغرافية
العنوان: Neuroendocrine breast carcinoma: a rare but challenging entity.
المؤلفون: Trevisi E; Department of Oncology, University of Turin, San Luigi Gonzaga Hospital, Regione Gonzole 10, 10043, Orbassano, Turin, Italy. elenatrevisi@gmail.com., La Salvia A; Department of Oncology, University Hospital, 12 de Octubre, Madrid, Spain., Daniele L; Pathology Unit, Ordine Mauriziano Hospital, Torino, Italy., Brizzi MP; Department of Oncology, University of Turin, San Luigi Gonzaga Hospital, Regione Gonzole 10, 10043, Orbassano, Turin, Italy., De Rosa G; Pathology Unit, Ordine Mauriziano Hospital, Torino, Italy., Scagliotti GV; Department of Oncology, University of Turin, San Luigi Gonzaga Hospital, Regione Gonzole 10, 10043, Orbassano, Turin, Italy., Di Maio M; Department of Oncology, University of Turin, Ordine Mauriziano Hospital, Torino, Italy.
المصدر: Medical oncology (Northwood, London, England) [Med Oncol] 2020 Jul 25; Vol. 37 (8), pp. 70. Date of Electronic Publication: 2020 Jul 25.
نوع المنشور: Journal Article; Review
اللغة: English
بيانات الدورية: Publisher: Springer Country of Publication: United States NLM ID: 9435512 Publication Model: Electronic Cited Medium: Internet ISSN: 1559-131X (Electronic) Linking ISSN: 13570560 NLM ISO Abbreviation: Med Oncol Subsets: MEDLINE
أسماء مطبوعة: Publication: 2011- : New York : Springer
Original Publication: Northwood, Middlesex, England : Science and Technology Letters, c1994-
مواضيع طبية MeSH: Breast Neoplasms/*pathology , Carcinoma, Neuroendocrine/*pathology , Rare Diseases/*pathology, Breast Neoplasms/genetics ; Breast Neoplasms/metabolism ; Carcinoma, Neuroendocrine/genetics ; Carcinoma, Neuroendocrine/metabolism ; Female ; Humans ; Neoplasm Grading ; Rare Diseases/genetics ; Rare Diseases/metabolism ; Receptors, Estrogen/metabolism
مستخلص: Breast carcinoma with neuroendocrine differentiation, also known as neuroendocrine breast carcinoma (NEBC), includes a heterogeneous group of rare tumors, which account for 2-5% of all invasive breast carcinomas. Because of their low incidence, most of the current limited knowledge of these tumors derives from anecdotal case reports or small retrospective series. The diagnosis of NEBC is based on the presence of morphological features similar to gastrointestinal and lung NETs and neuroendocrine markers. NEBCs are usually hormone receptors positive and HER2 negative, but despite this luminal phenotype, most recent studies suggested that NEBC could be associated with worse prognosis compared to invasive breast cancer without neuroendocrine differentiation. Due to its rarity and lack of randomized data, there is little evidence to guide the choice of treatment, so NEBC is currently treated as any invasive breast carcinoma not-otherwise specified. Recently, attempts to molecularly characterize NEBC have been made, in order to provide new targets for a more personalized treatment of this uncommon entity.
References: Nature. 2012 Oct 4;490(7418):61-70. (PMID: 23000897)
Br Med J. 1975 Oct 25;4(5990):197-9. (PMID: 1191996)
Cancer. 1978 May;41(5):2002-7. (PMID: 647636)
Breast Cancer. 2014 Jul;21(4):508-13. (PMID: 21735237)
J Breast Health. 2014 Oct 1;10(4):242-244. (PMID: 28331679)
Breast Care (Basel). 2012 Oct;7(5):408-10. (PMID: 24647781)
Lancet. 2016 Mar 5;387(10022):968-977. (PMID: 26703889)
Breast J. 2010 Nov-Dec;16(6):647-51. (PMID: 21070442)
Clin Breast Cancer. 2012 Aug;12(4):300-3. (PMID: 22513033)
Breast Cancer Res Treat. 2005 Jul;92(2):175-86. (PMID: 15986128)
Chest. 2013 Apr;143(4):955-962. (PMID: 23187897)
N Engl J Med. 2019 May 16;380(20):1929-1940. (PMID: 31091374)
Ann Diagn Pathol. 2019 Feb;38:62-66. (PMID: 30476894)
Breast Cancer Res Treat. 2014 Dec;148(3):637-44. (PMID: 25399232)
J Pathol. 1986 Jan;148(1):35-43. (PMID: 3003312)
Histopathology. 1980 Nov;4(6):613-30. (PMID: 6254868)
Semin Diagn Pathol. 2010 Feb;27(1):69-76. (PMID: 20306832)
Clin Breast Cancer. 2019 Apr;19(2):131-136. (PMID: 30268765)
Med Oncol. 2012 Dec;29(4):2613-8. (PMID: 22467078)
N Engl J Med. 2016 Nov 3;375(18):1738-1748. (PMID: 27717303)
Hum Pathol. 2001 Jul;32(7):753-7. (PMID: 11486176)
Breast J. 2015 May-Jun;21(3):303-7. (PMID: 25823996)
Ultrastruct Pathol. 1993 Jan-Feb;17(1):115-21. (PMID: 8427027)
Frankf Z Pathol. 1963 Oct 3;73:24-39. (PMID: 14097474)
J Pathol. 2017 Feb;241(3):405-419. (PMID: 27925203)
Histopathology. 2016 Feb;68(3):422-32. (PMID: 26114478)
Clin Imaging. 2014 Sep-Oct;38(5):734-8. (PMID: 25052497)
Hum Pathol. 2003 Oct;34(10):1001-8. (PMID: 14608533)
Breast J. 2015 May-Jun;21(3):312-3. (PMID: 25808825)
Breast J. 2017 Sep;23(5):589-593. (PMID: 28252252)
Am J Pathol. 1985 Aug;120(2):186-92. (PMID: 4025508)
Front Neuroendocrinol. 1999 Jul;20(3):157-98. (PMID: 10433861)
Mod Pathol. 2018 Jan;31(1):68-82. (PMID: 28884749)
Hum Pathol. 2011 Aug;42(8):1169-77. (PMID: 21334720)
Int J Surg Case Rep. 2017;38:29-31. (PMID: 28734185)
J Med Case Rep. 2010 Jun 30;4:201. (PMID: 20591162)
Dtsch Med Wochenschr. 1999 Feb 19;124(7):182-6. (PMID: 10093577)
Regul Pept. 2010 Nov 30;165(1):12-20. (PMID: 20211659)
Int J Surg. 2013;11 Suppl 1:S79-83. (PMID: 24380560)
Anticancer Res. 2012 Nov;32(11):5079-82. (PMID: 23155283)
Onco Targets Ther. 2014 May 06;7:663-6. (PMID: 24851054)
Breast Cancer Res Treat. 2016 Jul;158(1):195-202. (PMID: 27329168)
Breast Cancer. 2015 Jul;22(4):432-6. (PMID: 22711316)
Breast. 2014 Apr;23(2):120-7. (PMID: 24342375)
Korean J Radiol. 2013 May-Jun;14(3):395-9. (PMID: 23690703)
Breast J. 2020 Mar;26(3):505-507. (PMID: 31513314)
Case Rep Pathol. 2013;2013:204065. (PMID: 23738176)
BMC Cancer. 2017 Jan 24;17(1):72. (PMID: 28118820)
Cancer. 1981 Apr 1;47(7):1823-7. (PMID: 6261928)
Eur Radiol. 2003 Apr;13(4):788-93. (PMID: 12664118)
Proc (Bayl Univ Med Cent). 2018 May 9;31(3):352-354. (PMID: 29904310)
Int J Surg Case Rep. 2014;5(8):540-3. (PMID: 25024021)
World J Surg Oncol. 2013 Jun 05;11:128. (PMID: 23734899)
Anticancer Res. 2012 Jan;32(1):183-8. (PMID: 22213305)
Appl Immunohistochem Mol Morphol. 2015 Feb;23(2):97-103. (PMID: 25679062)
Breast Cancer. 2007;14(2):250-3. (PMID: 17485914)
J Clin Oncol. 2008 Sep 10;26(26):4311-8. (PMID: 18779618)
Pathol Int. 2011 Jan;61(1):49-51. (PMID: 21166944)
J Med Case Rep. 2017 Oct 19;11(1):290. (PMID: 29047418)
Breast J. 2019 May;25(3):519-520. (PMID: 31001910)
Radiol Case Rep. 2017 Jan 05;12(1):1-12. (PMID: 28228868)
Breast J. 2013 Mar-Apr;19(2):204-6. (PMID: 23458218)
Endocr Relat Cancer. 2016 Mar;23(3):191-9. (PMID: 26743120)
Surg Today. 2011 Jun;41(6):829-31. (PMID: 21626331)
N Engl J Med. 2017 Jan 12;376(2):125-135. (PMID: 28076709)
Int J Clin Exp Pathol. 2010 Jun 30;3(6):629-33. (PMID: 20661411)
Anticancer Res. 2014 Aug;34(8):3997-4003. (PMID: 25075022)
Semin Diagn Pathol. 1989 May;6(2):174-88. (PMID: 2503862)
Clin Breast Cancer. 2014 Oct;14(5):e99-e101. (PMID: 24958323)
BMC Cancer. 2014 Mar 04;14:147. (PMID: 24589259)
Eur J Nucl Med Mol Imaging. 2015 Dec;42(13):1964-70. (PMID: 26253273)
Neoplasma. 2013;60(2):215-22. (PMID: 23259792)
Breast. 2004 Aug;13(4):329-33. (PMID: 15325669)
N Engl J Med. 2020 Feb 6;382(6):514-524. (PMID: 31826360)
Int J Surg. 2008;6 Suppl 1:S113-5. (PMID: 19167937)
Oncol Lett. 2011 Sep 1;2(5):887-890. (PMID: 22866145)
Ann Oncol. 2018 Aug 1;29(8):1634-1657. (PMID: 30032243)
Surg Today. 2011 Nov;41(11):1575-8. (PMID: 21969166)
Pathol Int. 2019 Aug;69(8):502-504. (PMID: 31338942)
N Engl J Med. 2015 Jul 16;373(3):209-19. (PMID: 26030518)
Virchows Arch A Pathol Anat Histopathol. 1984;404(2):213-21. (PMID: 6091325)
Breast Care (Basel). 2015 Aug;10(4):281-3. (PMID: 26600766)
Cancer Res. 2005 Apr 1;65(7):2554-9. (PMID: 15805248)
N Engl J Med. 2012 Feb 9;366(6):520-9. (PMID: 22149876)
J Pathol. 2008 Oct;216(2):141-50. (PMID: 18720457)
Neuroendocrinology. 2017 Mar 30;105(3):212-244. (PMID: 28355596)
Histopathology. 2002 Mar;40(3):215-22. (PMID: 11895486)
Breast Care (Basel). 2016 Dec;11(6):424-426. (PMID: 28228710)
J Clin Oncol. 2017 Jul 1;35(19):2141-2148. (PMID: 28291390)
Clin Imaging. 2012 Sep-Oct;36(5):599-601. (PMID: 22920370)
Front Med. 2015 Mar;9(1):112-6. (PMID: 25098433)
Clin Breast Cancer. 2011 Oct;11(5):342-5. (PMID: 21729664)
Clin Nucl Med. 2014 Apr;39(4):396-8. (PMID: 24566407)
J Clin Oncol. 2009 Oct 1;27(28):4656-63. (PMID: 19704057)
Cancer. 2010 Oct 1;116(19):4463-73. (PMID: 20572042)
فهرسة مساهمة: Keywords: Breast cancer; Neuroendocrine breast carcinoma; Neuroendocrine differentiation; Neuroendocrine tumor; Small cell breast cancer
المشرفين على المادة: 0 (Receptors, Estrogen)
تواريخ الأحداث: Date Created: 20200727 Date Completed: 20210624 Latest Revision: 20210624
رمز التحديث: 20231215
مُعرف محوري في PubMed: PMC7382662
DOI: 10.1007/s12032-020-01396-4
PMID: 32712767
قاعدة البيانات: MEDLINE
الوصف
تدمد:1559-131X
DOI:10.1007/s12032-020-01396-4